Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2,279 Mln
P/E Ratio
--
P/B Ratio
10.42
Industry P/E
--
Debt to Equity
2.06
ROE
-0.94 %
ROCE
-39.43 %
Div. Yield
0 %
Book Value
1.84
EPS
-1.6
CFO
$-2,275.87 Mln
EBITDA
$-2,333.04 Mln
Net Profit
$-2,844.78 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals (APLS)
| -42.96 | -26.20 | -38.78 | -64.88 | -29.89 | -10.41 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals (APLS)
| -46.42 | 15.76 | 9.37 | -17.34 | 86.81 | 132.15 | -39.05 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.17 | 11,278.97 | 26.62 | 8.05 | |
| 62.24 | 6,815.49 | 52.52 | 23.56 | |
| 58.21 | 11,313.41 | 389.73 | 0.76 | |
| 7.56 | 8,821.37 | -- | -3.24 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of... paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451 Read more
Co-Founder, President, CEO & Director
Dr. Cedric Francois M.D., Ph.D.
Co-Founder, President, CEO & Director
Dr. Cedric Francois M.D., Ph.D.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Apellis Pharmaceuticals Inc (APLS) stood at $ 885 Mln as on 31-Dec-24
The share price of Apellis Pharmaceuticals Inc (APLS) is $18.20 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Apellis Pharmaceuticals Inc (APLS) has given a return of -29.89% in the last 3 years.
Apellis Pharmaceuticals Inc (APLS) has a market capitalisation of $ 2,279 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Apellis Pharmaceuticals Inc (APLS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Apellis Pharmaceuticals Inc (APLS) and enter the required number of quantities and click on buy to purchase the shares of Apellis Pharmaceuticals Inc (APLS).
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451
The CEO & director of Dr. Cedric Francois M.D., Ph.D.. is Apellis Pharmaceuticals Inc (APLS), and CFO & Sr. VP is Dr. Cedric Francois M.D., Ph.D..
There is no promoter pledging in Apellis Pharmaceuticals Inc (APLS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,140
|
|
|
1,139
|
|
|
930
|
|
|
770
|
| Apellis Pharmaceuticals Inc. (APLS) | Ratios |
|---|---|
|
Return on equity(%)
|
-93.55
|
|
Operating margin(%)
|
-33.55
|
|
Net Margin(%)
|
-27.87
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Apellis Pharmaceuticals Inc (APLS) was $0 Mln.
$0.04
(
